5GZ.F WAVERLEY PHARMA INC.

Healthcare Biotechnology Frankfurt Exchange
0.0123 EUR
Close of Nov 11, 2026
0.0040 0.0120
Market cap
EUR 662K
P/E
-
P/B
1.11x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 5GZ.F undervalued?

Graham number

The Graham number of WAVERLEY PHARMA INC. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

WAVERLEY PHARMA INC. fundamental analysis

No fundamental analysis for WAVERLEY PHARMA INC. yet.

WAVERLEY PHARMA INC. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About WAVERLEY PHARMA INC.

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

Full company profile